Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Fokus Mining Intersects 10 Metres Grading 10.06 G/T At The Galloway Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Kineta Inc KA

Healthcare Biotechnology
Kineta, Inc. is a clinical-stage biotechnology company. The Company has leveraged its expertise in innate immunity and is focused on discovering and developing potentially differentiated immunotherapies that address the mechanisms of cancer immune resistance: immunosuppression, exhausted T cells and poor tumor immunogenicity. Its pipeline of immunotherapies includes KVA12123, which is a... see more

Recent & Breaking News (NDAQ:KA)

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

GlobeNewswire 9 days ago

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire March 21, 2024

KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported

GlobeNewswire March 12, 2024

Kineta Announces Restructuring and Exploration of Strategic Alternatives

GlobeNewswire February 29, 2024

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

GlobeNewswire February 22, 2024

Kineta to Present at Upcoming Investor Conferences

GlobeNewswire February 14, 2024

Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series

GlobeNewswire February 7, 2024

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

GlobeNewswire January 17, 2024

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

GlobeNewswire January 4, 2024

Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer

GlobeNewswire December 13, 2023

Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023

GlobeNewswire November 28, 2023

Kineta to Present at the 5th Annual Macrophage-Directed Therapies Summit

GlobeNewswire November 9, 2023

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

GlobeNewswire November 6, 2023

Kineta Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 3, 2023

Kineta Presents New Preclinical Data on Lead Anti-CD27 Monoclonal Antibody at the Society for Immunotherapy of Cancer's (SITC) 38th Annual Meeting

GlobeNewswire November 3, 2023

Kineta Announces First Patient Dosed in Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

GlobeNewswire October 17, 2023

Kineta Announces KVA12123 and Anti-CD27 Agonist Antibody Abstracts Accepted for Poster Presentations at Society for Immunotherapy of Cancer (SITC) 2023

GlobeNewswire October 12, 2023

Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023

GlobeNewswire October 9, 2023

Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

GlobeNewswire October 5, 2023

Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy

GlobeNewswire October 4, 2023